Shang_2024_Mol.Imaging.Biol_26_729

Reference

Title : [(68)Ga]Ga-labeled FAPI Conjugated with Gly-Pro Sequence for PET Imaging of Malignant Tumors - Shang_2024_Mol.Imaging.Biol_26_729
Author(s) : Shang Y , Zhang G , Yao X , Lai C , Wang F , Zeng B , Liu E , Yuan H , Cheng Z , Jiang L
Ref : Mol Imaging Biol , 26 :729 , 2024
Abstract :

PURPOSE: To improve tumor uptake and prolong tumor retention, a novel fibroblast activation protein (FAP) ligand based on a quinoline-based FAP inhibitor (FAPI) conjugated with the Gly-Pro sequence and 1,4,7,10-tetraazacyclododecane-N,N',N'',N--tetraacetic acid (DOTA) was radiolabeled with [(68)Ga]GaCl(3) ([(68)Ga]Ga-DOTA-GPFAPI-04). Due to the tumor heterogeneity, this study aimed to further validate the preclinical value of [(68)Ga]Ga-DOTA-GPFAPI-04 PET imaging in tumor mice models with different FAP expression levels. METHODS: [(68)Ga]Ga-DOTA-GPFAPI-04 was synthesized and its partition coefficient was measured. The stability of [(68)Ga]Ga-DOTA-GPFAPI-04 was tested in phosphate-buffered saline (PBS, pH 7.4) and fetal bovine serum (FBS). Small animal PET and semi-quantitative studies were conducted in Panc-1 and A549 xenograft tumor mice models compared with [(68)Ga]Ga-DOTA-FAPI-04. Immunofluorescent and immunohistochemical staining and western blot assay were performed to confirm FAP expression in xenograft tumors. RESULTS: [(68)Ga]Ga-DOTA-GPFAPI-04 exhibited a radiochemical purity of > 99% and high stability in PBS and FBS. [(68)Ga]Ga-DOTA-GPFAPI-04 had higher hydrophilic property than [(68)Ga]Ga-DOTA-FAPI-04 (-4.09 +/- 0.05 vs -3.45 +/- 0.05). Small animal PET and semi-quantitative analysis revealed Panc-1 xenograft tumor displayed higher tumor uptake of [(68)Ga]Ga-DOTA-GPFAPI-04 and tumor-to-background ratios compared to A549 xenograft tumor, consistent with the results of immunofluorescence, immunohistochemistry, and western blot. Moreover, [(68)Ga]Ga-DOTA-GPFAPI-04 demonstrated higher tumor accumulation and longer tumor retention than [(68)Ga]Ga-DOTA-FAPI-04 in both Panc-1 and A549 xenograft tumors. Furthermore, the FAP-binding specificity of [(68)Ga]Ga-DOTA-GPFAPI-04 was confirmed in vivo by co-injection of unlabeled GPFAPI-04. CONCLUSION: [(68)Ga]Ga-DOTA-GPFAPI-04 showed more favorable in vivo tumor imaging and longer tumor retention compared to [(68)Ga]Ga-DOTA-FAPI-04, which has high potential to be a promising PET probe for detecting FAP-positive tumors.

PubMedSearch : Shang_2024_Mol.Imaging.Biol_26_729
PubMedID: 38987449

Related information

Inhibitor FAPI-04

Citations formats

Shang Y, Zhang G, Yao X, Lai C, Wang F, Zeng B, Liu E, Yuan H, Cheng Z, Jiang L (2024)
[(68)Ga]Ga-labeled FAPI Conjugated with Gly-Pro Sequence for PET Imaging of Malignant Tumors
Mol Imaging Biol 26 :729

Shang Y, Zhang G, Yao X, Lai C, Wang F, Zeng B, Liu E, Yuan H, Cheng Z, Jiang L (2024)
Mol Imaging Biol 26 :729